Published in Clin J Am Soc Nephrol on June 06, 2013
Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol (2014) 0.84
Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative. J Am Soc Nephrol (2016) 0.82
The kidney research predicament. J Am Soc Nephrol (2014) 0.81
Overcoming Barriers in Kidney Health-Forging a Platform for Innovation. J Am Soc Nephrol (2016) 0.79
Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther (2015) 0.78
Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis. Clin J Am Soc Nephrol (2013) 0.75
Stimulating Patient Engagement in Medical Device Development in Kidney Disease: A Report of a Kidney Health Initiative Workshop. Am J Kidney Dis (2017) 0.75
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
The FDA critical path initiative and its influence on new drug development. Annu Rev Med (2008) 4.08
The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol (2004) 3.30
Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol (2012) 3.23
Loss to analysis in randomized controlled trials in CKD. Am J Kidney Dis (2011) 2.85
Trial quality in nephrology: how are we measuring up? Am J Kidney Dis (2011) 1.32
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol (2006) 4.95
Focal segmental glomerulosclerosis. N Engl J Med (2011) 3.77
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
Hetastarch and bleeding complications after coronary artery surgery. Chest (2003) 2.87
Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med (2003) 2.85
The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med (2013) 2.77
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 2.41
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int (2004) 2.29
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol (2011) 2.18
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
How deceased donor transplantation is impacting a decline in commercial transplantation-the Tamil Nadu experience. Transplantation (2012) 2.14
Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol (2013) 2.06
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol (2013) 2.02
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis (2011) 1.92
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant (2007) 1.89
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest (2010) 1.87
Preoperative statin use and postoperative acute kidney injury. Am J Med (2012) 1.87
Educational level as a determinant of access to and outcomes after kidney transplantation in the United States. Am J Kidney Dis (2008) 1.84
Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med (2002) 1.82
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol (2011) 1.82
Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum (2013) 1.80
Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis (2013) 1.76
Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. Clin J Am Soc Nephrol (2010) 1.75
Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int (2009) 1.74
Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol (2002) 1.73
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 1.70
Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol (2012) 1.69
Variation in nephrologist visits to patients on hemodialysis across dialysis facilities and geographic locations. Clin J Am Soc Nephrol (2013) 1.69
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 1.68
The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis (2005) 1.67
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol (2005) 1.65
Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol (2009) 1.62
Anatomic configuration affects the flow rate and diameter of porcine arteriovenous fistulae. Kidney Int (2012) 1.58
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med (2014) 1.58
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) (2011) 1.57
SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med (2007) 1.56
The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int (2009) 1.54
Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant (2011) 1.54
Predicting survival in patients requiring renal replacement therapy after cardiac surgery. Ann Thorac Surg (2006) 1.53
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis (2003) 1.53
Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis (2009) 1.52
Long-term patient and graft survival in the eurotransplant senior program: a single-center experience. Transplantation (2005) 1.51
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol (2011) 1.51
Photoinstability of S-nitrosothiols during sampling of whole blood: a likely source of error and variability in S-nitrosothiol measurements. Clin Chem (2008) 1.48
Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother (2002) 1.48
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol (2006) 1.48
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol (2007) 1.46
Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf (2008) 1.45
Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol (2006) 1.43
Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol (2012) 1.42
Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes (2014) 1.41
C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol (2013) 1.38
Validation of reported predialysis nephrology care of older patients initiating dialysis. J Am Soc Nephrol (2012) 1.36
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
Early arteriovenous fistula failure: a logical proposal for when and how to intervene. Clin J Am Soc Nephrol (2005) 1.32
Knowledge and attitude regarding organ donation among medical students and physicians. Transplantation (2004) 1.31
Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis (2005) 1.31
Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis (2006) 1.28
Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol (2012) 1.27
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation (2010) 1.25
How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf (2004) 1.24
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff (Millwood) (2007) 1.22
Venous stenosis in a pig arteriovenous fistula model--anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant (2007) 1.22
Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age. Am J Cardiol (2007) 1.21
Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol (2006) 1.20
Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol (2011) 1.20
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation (2004) 1.18
Reimbursement of dialysis: a comparison of seven countries. J Am Soc Nephrol (2012) 1.17
Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem (2003) 1.17
End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum (2011) 1.17
ANCA are pathogenic--oh yes they are! J Am Soc Nephrol (2002) 1.15
Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol (2004) 1.14
The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One (2012) 1.14
Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol (2013) 1.12
Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int (2002) 1.12
Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum (2012) 1.11
Trends in acute kidney injury, associated use of dialysis, and mortality after cardiac surgery, 1999 to 2008. Ann Thorac Surg (2012) 1.10
Vascular access in haemodialysis: strengthening the Achilles' heel. Nat Rev Nephrol (2013) 1.09
Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study. J Vasc Surg (2009) 1.07
Saving the kidneys by sparing intravenous chloride? JAMA (2012) 1.07
Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis (2009) 1.07
Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens (2011) 1.06
Comparison of Medicare claims versus physician adjudication for identifying stroke outcomes in the Women's Health Initiative. Stroke (2014) 1.05
The 2011 ESRD prospective payment system: an uncontrolled experiment. Am J Kidney Dis (2011) 1.05
Differences in access to kidney transplantation between Hispanic and non-Hispanic whites by geographic location in the United States. Clin J Am Soc Nephrol (2013) 1.05
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int (2003) 1.05
NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol (2008) 1.04
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation (2002) 1.03
ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int (2008) 1.02
Clinical epidemiology of arteriovenous fistula in 2007. J Nephrol (2007) 1.02
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant (2005) 1.02